The last 27 October, the Italian Medicines Agency (AIFA) has provided, to the Exscalate4cov...
Exscalate4Cov (E4C) is a private-public consortium supported by the European Commission’s Horizon 2020 programme. The E4C aim is to contrast the pandemic by identifying an effective treatment against Covid-19.
To improve and speed up the research, the project combines the supercomputing resources of the most powerful supercomputer in Europe with some of the continent’s best life-science research labs. At the core of E4C there is Exscalate (EXaSCale smArt pLatform Against paThogEns), the most powerful (and cost-efficient) intelligent supercomputing platform in the world, developed by Dompé Farmaceutici SpA. E4C leverages a “chemical library” of 500 billion molecules, thanks to a processing capacity of more than 3 million molecules per second.
In the last months, a promising molecule in the fight against the pandemic has been selected: raloxifene.
The last 27 October, the Italian Medicines Agency (AIFA) has approved the human clinical trials with the raloxifene to treat patients COVID-19 with mild symptoms.
Last June, the Exscalate4cov consortium announced an important result in the fight against COVID-19...